Pfizer Clinical Trials
From scattered study pages to a living recruitment system
2020
During the first year of COVID-19, Pfizer and BioNTech compressed a decade of vaccine development into about eleven months. That timeline only works if you can find and enroll tens of thousands of volunteers into clinical trials at speed—and recruitment is usually the slowest part of the process. Around 80% of trials struggle to meet enrollment timelines, and recruitment often accounts for a third of overall trial costs.
At VMLY&R, I led the experience design for a key piece of Pfizer’s digital recruitment journey: the patient-facing experience that explained what it meant to join a trial and guided people into a focused “Next Steps” funnel.
The Moment of Truth in a Pandemic
When the Phase 3 Pfizer–BioNTech vaccine trial launched in July 2020, the target was roughly 44,000 participants across ~150 sites in six countries. Data needed to accrue fast enough to prove efficacy while the virus was still surging. That pressure landed squarely on the enrollment machine.
Our slice of that machine was deceptively simple: a web journey where a person at home—anxious, overloaded, maybe sceptical—could understand what a trial actually involved and decide whether to step forward.
Legal and regulatory content stayed intact, but the narrative was rebuilt for humans.
During the height of the vaccine race, that experience recorded 121,000 clicks on “Next Steps”—121,000 people actively signalling “I’m willing to be considered” in the middle of a global emergency. In parallel, the Phase 3 trial enrolled more than 43,000 participants and delivered the data that led to the first COVID-19 vaccine authorizations in the UK, US and EU.
That’s the immediate story: a precise piece of UX helping to feed the enrolment engine behind a historic vaccine.
121K+
Recorded clicks on “Next Steps”
A Front Door for Every Trial
The deeper story is that this work was never only about COVID.
The “Next Steps” experience lives inside PfizerClinicalTrials.com, the unified front door for Pfizer’s research portfolio: vaccines, oncology, internal medicine, pediatrics, rare diseases, and more. The same patterns we defined for clarity, consent, and action are used when someone is exploring a flu booster study, a novel oncology regimen, or a rare-disease trial.
COVID-19 was the stress test that proved the system under maximum load. Once the headlines moved on, the platform stayed—and kept working.
Today, that front door continues to direct people to studies that refine dosing, expand indications, and validate new therapies. It helps researchers move beyond underpowered trials and narrow demographics. It helps patients and caregivers see research as something they can understand and realistically participate in, not a black box reserved for “other” people.
In the first year of the pandemic, the experience we built helped a vaccine reach the world faster. Now, embedded in Pfizer’s ongoing clinical operations, it continues to support trials that shape care and help save millions of lives over time.